1993至2016年Medicare人群皮肤活检与皮肤癌治疗使用趋势
该回顾性横断面研究分析Medicare按服务收费人群1993至2016年理赔数据,发现每1000名受益人皮肤活检数增加153%(39.31至99.33),皮肤癌治疗数增加39%(34.67至48.26),活检与治疗比值增加81%(1.134至2.058)。2001至2016年间高级执业人员活检数从0.82增至17.19(1996%),皮肤科医生从53.98增至76.17(41%)。
要点
- 皮肤活检增速远超皮肤癌治疗,提示部分活检未导致癌症诊断或治疗。
- 高级执业人员活检量增长1996%,远高于皮肤科医生的41%。
- 皮肤活检与皮肤癌治疗比值从1.134升至2.058,增加81%。
核心结论
- 皮肤活检数自1993年以来增加153%,而皮肤癌治疗数仅增加39%,提示活检使用增加且部分活检未导致皮肤癌诊断或治疗。
- 高级执业人员可能因活检更多良性病变而增加皮肤癌管理成本。
研究设计与样本
- 回顾性横断面研究,使用Centers for Medicare and Medicaid Services Physician Claims数据库分析Medicare按服务收费付费理赔数据。
- 计算1993至2016年皮肤活检和皮肤癌治疗数量,以及2001至2016年按提供者类型的使用百分比。
主要发现
- 每1000名Medicare FFS受益人皮肤活检数从39.31增至99.33,增加153%。
- 每1000名Medicare FFS受益人皮肤癌治疗数从34.67增至48.26,增加39%。
- 皮肤活检与皮肤癌治疗比值从1.134增至2.058,增加81%。
- 每1000名受益人额外活检数从4.638增至51.072,增加1001%。
- 2001至2016年,高级执业人员每1000名受益人活检数从0.82增至17.19(1996%),皮肤科医生从53.98增至76.17(41%)。
临床怎么用
- 临床应关注皮肤活检适应症,避免不必要的活检以控制成本和患者负担。
- 比较皮肤科医生与高级执业人员的活检准确性,优化皮肤癌管理流程。
局限性
- Medicare理赔数据未提供皮肤活检或皮肤癌治疗使用的具体信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Skin biopsies are increasing at a rapid rate, and some may be unnecessary. Although skin cancer incidence is rising, there is varied biopsy accuracy between dermatologists and advanced practice professionals (APPs). A comparison of Current Procedural Terminology code (American Medical Association, Chicago, IL) use for skin biopsy and skin cancer treatment over 18 years and a comparison of provider types is needed. Excess skin biopsies increase health care costs and patient morbidity. OBJECTIVE: To examine changes in skin biopsy and skin cancer treatment utilization rates per year in the Medicare fee-for-service (FFS) population and to compare skin biopsy utilization rates between dermatologists and APPs. METHODS: Retrospective cross-sectional study of Medicare FFS paid claims using the Centers for Medicare and Medicaid Services Physician Claims databases. We calculated the number of skin biopsies and skin cancer treatments in the Medicare FFS population from 1993 to 2016, and percentage use by provider type from 2001 to 2016. Our primary outcome measurements were the number of skin biopsies and skin cancer treatments per 1000 Medicare FFS beneficiaries per year and the number of additional skin biopsies per 1000 Medicare FFS beneficiaries per year, or the difference in the number of skin biopsies and number of skin cancer treatments per 1000 Medicare FFS beneficiaries. Our secondary outcome measurements were the skin biopsy-to-skin cancer treatment ratio and the number of procedures per 1000 Medicare FFS beneficiaries per year by provider type. RESULTS: After adjusting for the number of enrollees in the Medicare FFS population from 1993 to 2016, skin biopsies per 1000 Medicare FFS beneficiaries increased 153% (from 39.31 to 99.33), and skin cancer treatments per 1000 Medicare FFS beneficiaries increased 39% (from 34.67 to 48.26). Between 1993 and 2016, the skin biopsy-to-skin cancer treatment ratio increased 81% (from 1.134 to 2.058), and the number of additional biopsies per 1000 Medicare FFS beneficiaries increased 1001% (from 4.638 to 51.072) between 1993 and 2016. Utilization data by provider type is available from 2001 to 2016. The number of skin biopsies per 1000 Medicare beneficiaries performed by APPs increased from 0.82 to 17.19 or 1996% (nurse practitioners, 2211%; physician assistants, 1916%) and the number of biopsies by dermatologists increased by 41% from 53.98 to 76.17. LIMITATIONS: Medicare claims data do not provide specific information regarding skin biopsy or skin cancer treatment use. CONCLUSION: The number of skin biopsies has risen 153% since 1993, while the number of skin cancer treatments has only increased 39%. Our data highlight the rise of biopsy use and the increase in biopsies that do not result in skin cancer diagnosis or treatment. This suggests APPs may be responsible for increasing the cost of skin cancer management by biopsying significantly more benign lesions than dermatologists.
引用
- Skaggs R, Coldiron B. Skin biopsy and skin cancer treatment use in the Medicare population, 1993 to 2016. J Am Acad Dermatol. 2020. PMID: 32553682. doi:10.1016/j.jaad.2020.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。